Selected research
Industry Research
Injectable Suspension Budesonide Industry Research Report 2026
Market perspective
The global Injectable Suspension Budesonide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Injectable Suspension Budesonide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Injectable Suspension Budesonide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Injectable Suspension Budesonide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Injectable Suspension Budesonide include Teva, Shanghai Sine Promod, Sandoz, Mylan, Lunan Better Pharma, Synmosa Biopharma, AstraZeneca, Salix and Orion Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Injectable Suspension Budesonide market in terms of revenue (US$ million) and, where applicable, sales volume (K L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K L) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Injectable Suspension Budesonide Market by Company
Teva
Shanghai Sine Promod
Sandoz
Mylan
Lunan Better Pharma
Synmosa Biopharma
AstraZeneca
Salix
Orion Corporation
Cosmo Pharmaceuticals
Cipla
Chiesi Farmaceutici
Injectable Suspension Budesonide Segment by Type
0.5mg
1mg
Injectable Suspension Budesonide Segment by Application
Inflammatory Bowel Disease Treatment
Respiratory Disease Treatment
Nose Disease Treatment
Other
Injectable Suspension Budesonide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable Suspension Budesonide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Injectable Suspension Budesonide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable Suspension Budesonide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Injectable Suspension Budesonide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Injectable Suspension Budesonide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Injectable Suspension Budesonide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.5mg
- 1mg
Applications
- Inflammatory Bowel Disease Treatment
- Respiratory Disease Treatment
- Nose Disease Treatment
- Other
Companies covered
- Teva
- Shanghai Sine Promod
- Sandoz
- Mylan
- Lunan Better Pharma
- Synmosa Biopharma
- AstraZeneca
- Salix
- Orion Corporation
- Cosmo Pharmaceuticals
- Cipla
- Chiesi Farmaceutici
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Injectable Suspension Budesonide Market Size (2021-2032)
- 2.2.2 Global Injectable Suspension Budesonide Sales (2021-2032)
- 2.2.3 Global Injectable Suspension Budesonide Market Average Price (2021-2032)
- 2.3 Injectable Suspension Budesonide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 0.5mg
- 2.3.3 1mg
- 2.4 Injectable Suspension Budesonide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Inflammatory Bowel Disease Treatment
- 2.4.3 Respiratory Disease Treatment
- 2.4.4 Nose Disease Treatment
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Injectable Suspension Budesonide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Injectable Suspension Budesonide Sales (K L) of Manufacturers (2021-2026)
- 3.3 Global Injectable Suspension Budesonide Revenue of Manufacturers (2021-2026)
- 3.4 Global Injectable Suspension Budesonide Average Price by Manufacturers (2021-2026)
- 3.5 Global Injectable Suspension Budesonide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Injectable Suspension Budesonide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Injectable Suspension Budesonide, Product Type & Application
- 3.8 Global Manufacturers of Injectable Suspension Budesonide, Established Date
- 3.9 Global Injectable Suspension Budesonide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Injectable Suspension Budesonide Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Shanghai Sine Promod
- 4.2.1 Shanghai Sine Promod Company Information
- 4.2.2 Shanghai Sine Promod Business Overview
- 4.2.3 Shanghai Sine Promod Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai Sine Promod Injectable Suspension Budesonide Product Portfolio
- 4.2.5 Shanghai Sine Promod Recent Developments
- 4.3 Sandoz
- 4.3.1 Sandoz Company Information
- 4.3.2 Sandoz Business Overview
- 4.3.3 Sandoz Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sandoz Injectable Suspension Budesonide Product Portfolio
- 4.3.5 Sandoz Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Injectable Suspension Budesonide Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Lunan Better Pharma
- 4.5.1 Lunan Better Pharma Company Information
- 4.5.2 Lunan Better Pharma Business Overview
- 4.5.3 Lunan Better Pharma Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lunan Better Pharma Injectable Suspension Budesonide Product Portfolio
- 4.5.5 Lunan Better Pharma Recent Developments
- 4.6 Synmosa Biopharma
- 4.6.1 Synmosa Biopharma Company Information
- 4.6.2 Synmosa Biopharma Business Overview
- 4.6.3 Synmosa Biopharma Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Synmosa Biopharma Injectable Suspension Budesonide Product Portfolio
- 4.6.5 Synmosa Biopharma Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Injectable Suspension Budesonide Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
- 4.8 Salix
- 4.8.1 Salix Company Information
- 4.8.2 Salix Business Overview
- 4.8.3 Salix Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Salix Injectable Suspension Budesonide Product Portfolio
- 4.8.5 Salix Recent Developments
- 4.9 Orion Corporation
- 4.9.1 Orion Corporation Company Information
- 4.9.2 Orion Corporation Business Overview
- 4.9.3 Orion Corporation Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Orion Corporation Injectable Suspension Budesonide Product Portfolio
- 4.9.5 Orion Corporation Recent Developments
- 4.10 Cosmo Pharmaceuticals
- 4.10.1 Cosmo Pharmaceuticals Company Information
- 4.10.2 Cosmo Pharmaceuticals Business Overview
- 4.10.3 Cosmo Pharmaceuticals Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cosmo Pharmaceuticals Injectable Suspension Budesonide Product Portfolio
- 4.10.5 Cosmo Pharmaceuticals Recent Developments
- 4.11 Cipla
- 4.11.1 Cipla Company Information
- 4.11.2 Cipla Business Overview
- 4.11.3 Cipla Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cipla Injectable Suspension Budesonide Product Portfolio
- 4.11.5 Cipla Recent Developments
- 4.12 Chiesi Farmaceutici
- 4.12.1 Chiesi Farmaceutici Company Information
- 4.12.2 Chiesi Farmaceutici Business Overview
- 4.12.3 Chiesi Farmaceutici Injectable Suspension Budesonide Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Chiesi Farmaceutici Injectable Suspension Budesonide Product Portfolio
- 4.12.5 Chiesi Farmaceutici Recent Developments
5 Global Injectable Suspension Budesonide Market Scenario by Region
- 5.1 Global Injectable Suspension Budesonide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Injectable Suspension Budesonide Sales by Region: 2021-2032
- 5.2.1 Global Injectable Suspension Budesonide Sales by Region: 2021-2026
- 5.2.2 Global Injectable Suspension Budesonide Sales by Region: 2027-2032
- 5.3 Global Injectable Suspension Budesonide Revenue by Region: 2021-2032
- 5.3.1 Global Injectable Suspension Budesonide Revenue by Region: 2021-2026
- 5.3.2 Global Injectable Suspension Budesonide Revenue by Region: 2027-2032
- 5.4 North America Injectable Suspension Budesonide Market Facts & Figures by Country
- 5.4.1 North America Injectable Suspension Budesonide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Injectable Suspension Budesonide Sales by Country (2021-2032)
- 5.4.3 North America Injectable Suspension Budesonide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Injectable Suspension Budesonide Market Facts & Figures by Country
- 5.5.1 Europe Injectable Suspension Budesonide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Injectable Suspension Budesonide Sales by Country (2021-2032)
- 5.5.3 Europe Injectable Suspension Budesonide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Injectable Suspension Budesonide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Injectable Suspension Budesonide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Injectable Suspension Budesonide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Injectable Suspension Budesonide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Injectable Suspension Budesonide Market Facts & Figures by Country
- 5.7.1 South America Injectable Suspension Budesonide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Injectable Suspension Budesonide Sales by Country (2021-2032)
- 5.7.3 South America Injectable Suspension Budesonide Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Injectable Suspension Budesonide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Injectable Suspension Budesonide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Injectable Suspension Budesonide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Injectable Suspension Budesonide Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Injectable Suspension Budesonide Sales by Type (2021-2032)
- 6.1.1 Global Injectable Suspension Budesonide Sales by Type (2021-2032) & (K L)
- 6.1.2 Global Injectable Suspension Budesonide Sales Market Share by Type (2021-2032)
- 6.2 Global Injectable Suspension Budesonide Revenue by Type (2021-2032)
- 6.2.1 Global Injectable Suspension Budesonide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Injectable Suspension Budesonide Revenue Market Share by Type (2021-2032)
- 6.3 Global Injectable Suspension Budesonide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Injectable Suspension Budesonide Sales by Application (2021-2032)
- 7.1.1 Global Injectable Suspension Budesonide Sales by Application (2021-2032) & (K L)
- 7.1.2 Global Injectable Suspension Budesonide Sales Market Share by Application (2021-2032)
- 7.2 Global Injectable Suspension Budesonide Revenue by Application (2021-2032)
- 7.2.1 Global Injectable Suspension Budesonide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Injectable Suspension Budesonide Revenue Market Share by Application (2021-2032)
- 7.3 Global Injectable Suspension Budesonide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Injectable Suspension Budesonide Value Chain Analysis
- 8.1.1 Injectable Suspension Budesonide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Injectable Suspension Budesonide Production Mode & Process
- 8.2 Injectable Suspension Budesonide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Injectable Suspension Budesonide Distributors
- 8.2.3 Injectable Suspension Budesonide Customers
9 Global Injectable Suspension Budesonide Analyzing Market Dynamics
- 9.1 Injectable Suspension Budesonide Industry Trends
- 9.2 Injectable Suspension Budesonide Industry Drivers
- 9.3 Injectable Suspension Budesonide Industry Opportunities and Challenges
- 9.4 Injectable Suspension Budesonide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst